Back HCV Treatment

HCV Treatment

Coverage of the 2014 EASL International Liver Congress

HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.

Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.

Full listing by topic

Conference web site

4/13/14

alt

EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.

alt

Read more:

EASL 2014: AbbVie Oral Regimen Cures 96% of Treatment-experienced Genotype 1 Patients

A 12-week course of 3 direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1, Stefan Zeuzem of the J.W. Goethe University Hospital in Frankfurt reported on Thursday at the 49th EASL International Liver Congress in London.

alt

Read more:

EASL 2014: Sofosbuvir + Ledipasvir Cures More than 90% of First-time and Retreated Genotype 1 Patients

A coformulation of sofosbuvir and ledipasvir taken for as little as 8 weeks produced high sustained response rates across the board for participants in the Phase 3 ION trials, including people with HCV genotype 1 starting treatment for the first time, prior non-responders, and people with liver cirrhosis, according to findings presented this week at the 49thEASL International Liver Congress in London. Results were also published online in the New England Journal of Medicine.

alt

Read more:

EASL 2014: Sofosbuvir + Ledipasvir Is Safe and Effective for Relapsers and Hard-to-Treat Hep C Patients

A coformulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, patients with decompensated cirrhosis, and people who were not cured with previous sofosbuvir-containing therapy, according to a series of studies presented at the 49thEASL International Liver Congress (EASL 2014) this week in London.

alt

Read more: